Summary of DBV Technologies S.A. (NASDAQ:DBVT) Ratings as of May 17, 2018

May 17, 2018 - By Darrel Chase

DBV Technologies S.A. (NASDAQ:DBVT) Corporate Logo

DBV Technologies S.A. (NASDAQ:DBVT) Ratings Coverage

Total analysts of 3 have positions in DBV Technologies SA – American (NASDAQ:DBVT) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since February 14, 2018 according to StockzIntelligence Inc DBV Technologies SA – American has 3 analyst reports. In Thursday, March 15 report H.C. Wainwright maintained the stock with “Buy” rating. On Tuesday, March 27 the rating was maintained by Deutsche Bank with “Buy”. Listed here are DBV Technologies S.A. (NASDAQ:DBVT) PTs and latest ratings.

27/03/2018 Broker: Deutsche Bank Rating: Buy New Target: $33.0000 Maintain
15/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $50.0 Maintain
14/02/2018 Broker: Citigroup Rating: Buy New Target: $57.0

Ticker’s shares touched $24.84 during the last trading session after 0.40% change.DBV Technologies S.A. has volume of 50,734 shares. Since May 17, 2017 DBVT has declined 34.29% and is downtrending. DBVT underperformed the S&P500 by 45.84%.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.The firm is valued at $1.45 billion. The Company’s lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.Last it reported negative earnings. The firm is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cowÂ’s milk protein allergy and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of henÂ’s egg allergy; and booster vaccine for Bordatella pertussis.

DBV Technologies S.A. (NASDAQ:DBVT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.